ClinicalTrials.gg
TerminatedNCT01244620Updated Feb 22, 2012Results posted

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses

A Phase 1 interventional study of sitaxentan and tadalafil in Pulmonary Arterial Hypertension, sponsored by Pfizer. Terminated at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-22.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Pulmonary Arterial Hypertension by Pfizer — none open to participants now, none under way, none of them phase 3. Pulmonary Arterial Hypertension · Pfizer.

Started
2010
with 3 others
Phase 1
3 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Pulmonary Arterial Hypertension by Pfizer, this one is one of 4 that started in 2010, is one of 3 in phase 1, and was the 6th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 11 studies in Pulmonary Arterial Hypertension by Pfizer is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Pulmonary Arterial Hypertension by Pfizer as a file.
02

Study summary

Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).

Tadalafil did not have clinically relevant effect on pharmacokinetics of bosentan and ambrisentan. Based on overall clinical drug-drug interaction profiles, and in vitro CYP enzymes and transporter data, a clinically relevant drug-drug interaction between sitaxsentan and tadalafil is not expected. Sildenafil is not expected to affect sitaxsentan pharmacokinetics (PK), as sitaxsentan is a substrate of CYP3A4 and CYP2C9, where sildenafil did not show clinically relevant effect on PK of substrates of CYP3A4 and CYP2C9.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • A pharmacokinetic drug-drug interaction study between sitaxsentan and tadalafil and between sitaxsentan and sildenafil at the steady-state
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects and women of non-child bearing potential between the ages of 21 and 55 years, inclusive. Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead and clinical laboratory tests.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).
  • An document signed and dated by the subject or a legally acceptable representative.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or clinical findings at Screening.
  • A positive urine drug screen.
  • Subjects with hepatic dysfunction, defined as (AST) and/or alanine aminotransferase (ALT) >1.5 times the at Screening. A retest may be done if AST and/or ALT within 1.5- to 2- times the upper limit of the normal range at Screening, and the average of the first and repeated test values should be used to decide the eligibility.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment A

    sitaxsentan 100 mg QD for 6 days (Treatment A)

    Drug: sitaxentan

  • Experimental
    Treatment B

    tadalafil 40 mg QD for 6 days

    Drug: tadalafil

  • Experimental
    Treatment C

    sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days

    Drug: sitaxsentan · Drug: tadalafil

  • Experimental
    Treatment D

    sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days

    Drug: sitaxsentan · Drug: sildenafil

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

  2. Trough Plasma Concentrations (Ctrough)

    Minimum or "trough"concentrations

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

  3. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

  4. Area Under the Curve of the 24 Hour Dosing Interval (AUC24)

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

  5. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

  6. Volume of Distribution at Steady State (Vss)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

Secondary outcomes

  1. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)

07

Results

Posted Feb 22, 2012
Limitations and caveats
Study endpoints were not analyzed due to early termination.

Participant flow

The study was terminated for safety reasons (hepatoxicity) after dosing was completed for the first intervention.

Participant flow — Overall Study
MilestoneSitax, Then Tad, Then Sitax and Tad, Then Sitax and SildTad, Then Sitax and Sild, Then Sitax, Then Sitax and TadSitax and Tad, Then Sitax, Then Sitax and Sild, Then TadSitax and Sild, Then Sitax and Tad, Then Tad, Then Sitax
Started4444
Completed0000
Not completed4444
Withdrew: Study terminated4444

Outcome measures

PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Median · hours

No measurements were reported for this outcome.

PrimaryTrough Plasma Concentrations (Ctrough)

Minimum or "trough"concentrations

Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Geometric mean · nanograms (ng)/milliliter (mL)

No measurements were reported for this outcome.

PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)

No measurements were reported for this outcome.

PrimaryArea Under the Curve of the 24 Hour Dosing Interval (AUC24)
Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Geometric mean · nanogram hour per milliliter (ng*hr/mL)

No measurements were reported for this outcome.

PrimaryApparent Oral Clearance (CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Geometric mean · mL/minute

No measurements were reported for this outcome.

SecondaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Mean · hours

No measurements were reported for this outcome.

PrimaryVolume of Distribution at Steady State (Vss)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

Time frame:
Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Reported as:
Geometric mean · Liter (L)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitaxsentan—0/4 (0%)1/4 (25%)
Tadalafil—0/4 (0%)4/4 (100%)
Sitaxsentan and Tadalafil—0/4 (0%)4/4 (100%)
Sitaxsentan and Sildenafil—0/4 (0%)2/4 (50%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSitaxsentanTadalafilSitaxsentan and TadalafilSitaxsentan and Sildenafil
HeadacheNervous system disorders1/43/43/40/4
NauseaGastrointestinal disorders0/42/42/40/4
PyrexiaGeneral disorders0/42/42/41/4
Back painMusculoskeletal and connective tissue disorders0/42/40/40/4
MyalgiaMusculoskeletal and connective tissue disorders1/42/42/40/4
Head discomfortNervous system disorders0/42/40/40/4
InsomniaPsychiatric disorders0/41/42/40/4
Abdominal distensionGastrointestinal disorders1/40/40/40/4
DiarrhoeaGastrointestinal disorders1/40/41/41/4
DysphagiaGastrointestinal disorders0/41/41/41/4

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean31.9 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male16
08

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2010
First posted
Nov 19, 2010
Start
Nov 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Feb 22, 2012
Last update
Feb 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01244620
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2010
Start date
Nov 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Feb 22, 2012
Last update
Feb 22, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitaxsentan · Tadalafil · Sildenafil

Start the discussion